Stock Research for REGN

REGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

REGN Stock Chart & Research Data

The REGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the REGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


REGN Due diligence Resources & Stock Charts

The REGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View REGN Detailed Price Forecast - CNN Money CNN View REGN Detailed Summary - Google Finance
Yahoo View REGN Detailed Summary - Yahoo! Finance Zacks View REGN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View REGN Trends & Analysis - Trade-Ideas Barrons View REGN Major Holders - Barrons
NASDAQ View REGN Call Transcripts - NASDAQ Seeking View REGN Breaking News & Analysis - Seeking Alpha
Spotlight View REGN Annual Report - CompanySpotlight.com OTC Report View REGN OTC Short Report - OTCShortReport.com
TradeKing View REGN Fundamentals - TradeKing Charts View REGN SEC Filings - Bar Chart
WSJ View Historical Prices for REGN - The WSJ Morningstar View Performance/Total Return for REGN - Morningstar
MarketWatch View the Analyst Estimates for REGN - MarketWatch CNBC View the Earnings History for REGN - CNBC
StockMarketWatch View the REGN Earnings - StockMarketWatch MacroAxis View REGN Buy or Sell Recommendations - MacroAxis
Bullish View the REGN Bullish Patterns - American Bulls Short Pains View REGN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View REGN Stock Mentions - StockTwits PennyStocks View REGN Stock Mentions - PennyStockTweets
Twitter View REGN Stock Mentions - Twitter Invest Hub View REGN Investment Forum News - Investor Hub
Yahoo View REGN Stock Mentions - Yahoo! Message Board Seeking Alpha View REGN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for REGN - SECform4.com Insider Cow View Insider Transactions for REGN - Insider Cow
CNBC View REGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for REGN - OTC Markets
Yahoo View Insider Transactions for REGN - Yahoo! Finance NASDAQ View Institutional Holdings for REGN - NASDAQ


Stock Charts

FinViz View REGN Stock Insight & Charts - FinViz.com StockCharts View REGN Investment Charts - StockCharts.com
BarChart View REGN Stock Overview & Charts - BarChart Trading View View REGN User Generated Charts - Trading View




Latest Financial News for REGN


Regeneron's anti-blindness drug approved for less frequent treatments
Posted on Friday August 17, 2018

This marks a turnaround from earlier in the week when the U.S. regulator had issued a complete response letter which indicated it was not yet satisfied with the information provided by Regeneron. Regeneron did not give any reason for the change in its statement on Friday. Eylea is currently approved in wet AMD for dosing intervals of every four or eight weeks after three initial monthly doses.


FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Posted on Friday August 17, 2018

TARRYTOWN, N.Y., Aug. 17, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD). "We are pleased that the FDA has approved an updated label for EYLEA," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. EYLEA is also approved in wet AMD for every four- or eight-week dosing intervals after three initial monthly doses.


FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
Posted on Thursday August 16, 2018

Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.


Why Vertex Is Expected to Report Robust EPS Growth in 2018
Posted on Thursday August 16, 2018

How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.